Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Retained Earnings: 2022-2024

Historic Retained Earnings for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to -$554.1 million.

  • Day One Biopharmaceuticals' Retained Earnings fell 31.07% to -$640.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$640.1 million, marking a year-over-year decrease of 31.07%. This contributed to the annual value of -$554.1 million for FY2024, which is 20.82% down from last year.
  • Day One Biopharmaceuticals' Retained Earnings amounted to -$554.1 million in FY2024, which was down 20.82% from -$458.6 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Retained Earnings ranged from a high of -$269.7 million in FY2022 and a low of -$554.1 million during FY2024.
  • For the 3-year period, Day One Biopharmaceuticals' Retained Earnings averaged around -$427.4 million, with its median value being -$458.6 million (2023).
  • Data for Day One Biopharmaceuticals' Retained Earnings shows a maximum YoY tumbled of 70.06% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Retained Earnings stood at -$269.7 million in 2022, then crashed by 70.06% to -$458.6 million in 2023, then declined by 20.82% to -$554.1 million in 2024.